1.
Nat Hum Behav
; 6(2): 170, 2022 02.
Article
in English
| MEDLINE | ID: covidwho-2304075
2.
Nat Hum Behav
; 6(2): 171, 2022 02.
Article
in English
| MEDLINE | ID: covidwho-1661965
3.
CMAJ
; 193(36): E1446-E1447, 2021 09 13.
Article
in French
| MEDLINE | ID: covidwho-1609106
4.
BMJ
; 375: n2738, 2021 11 11.
Article
in English
| MEDLINE | ID: covidwho-1515274
Subject(s)
COVID-19 , Public Health , Vaccination Coverage , Vulnerable Populations , COVID-19/economics , COVID-19/epidemiology , COVID-19/prevention & control , Humans , Needs Assessment , New Zealand/epidemiology , Policy Making , Public Health/economics , Public Health/trends , Resource Allocation/methods , SARS-CoV-2 , Vaccination Coverage/organization & administration , Vaccination Coverage/standards , Vulnerable Populations/ethnology , Vulnerable Populations/statistics & numerical data
5.
Hong Kong Med J
; 27(2): 84-85, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1196138
Subject(s)
COVID-19 Vaccines , COVID-19 , Communicable Disease Control/standards , Immunity, Herd/drug effects , Immunization Programs , Vaccination Coverage , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19/transmission , COVID-19 Vaccines/classification , COVID-19 Vaccines/pharmacology , COVID-19 Vaccines/supply & distribution , Forecasting , Humans , Immunization Programs/methods , Immunization Programs/organization & administration , Immunization Programs/trends , Needs Assessment , Quality Improvement , SARS-CoV-2 , Vaccination Coverage/methods , Vaccination Coverage/standards
6.
Indian J Tuberc
; 68(2): 171-173, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1179680
Subject(s)
COVID-19 Vaccines , COVID-19 , Immunogenicity, Vaccine/immunology , SARS-CoV-2 , Vaccination Coverage , Viral Proteins/genetics , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19/virology , COVID-19 Vaccines/classification , COVID-19 Vaccines/pharmacology , Global Health , Humans , Mutation , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Vaccination Coverage/organization & administration , Vaccination Coverage/standards
7.
Br J Hosp Med (Lond)
; 82(2): 1-4, 2021 Feb 02.
Article
in English
| MEDLINE | ID: covidwho-1110766
ABSTRACT
The UK government recently decided to extend the interval between the first dose of the Pfizer BioNTech and AstraZeneca COVID-19 vaccines from 3 weeks to 12 weeks to maximise the number of people receiving the initial dose, despite the trials only providing vaccine efficacy data based on a schedule of 21 days between doses. This editorial discusses whether there is evidence to support this policy change.
Subject(s)
COVID-19 Vaccines , COVID-19 , Immunogenicity, Vaccine , Vaccination Coverage , Vaccination , COVID-19/epidemiology , COVID-19/immunology , COVID-19/prevention & control , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/immunology , Drug Administration Schedule , Evidence-Based Medicine/methods , Evidence-Based Medicine/standards , Government Regulation , Health Policy/legislation & jurisprudence , Humans , Policy Making , SARS-CoV-2 , United Kingdom/epidemiology , Vaccination/methods , Vaccination/standards , Vaccination/statistics & numerical data , Vaccination Coverage/methods , Vaccination Coverage/standards
8.
Res Nurs Health
; 44(2): 266-267, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1055946